The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...

High-intensity focused ultrasound (HIFU) is a noninvasive procedure commonly used for skin tightening. However, it has the potential to cause severe ocular complications(1, 2). A 29-year-old female ...

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth ...

Prof. Nicolas Barry-Delongchamps, Professor of Urology at Cochin Hospital and Principal Investigator of the VIOLETTE trial, will present the final results and one-year patients follow-up from the ...

Men suffering from the disruptive symptoms of an enlarged prostate now have a new treatment option available at East Georgia Regional Medical Center. The hospital has introduced a state-of-the-art, ...

URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

A pioneering feat of British medical innovation has seen a surgeon in London successfully remove a patient's prostate while the man lay on an operating table some 1,500 miles away in Gibraltar. Prof ...